Stephanie Gaillard, MD
Enriched profileAssociate Professor of Oncology and Associate Professor of Gynecology and Obstetrics, Director of Gynecologic Cancer Trials · Johns Hopkins School of Medicine
Stephanie Gaillard is Associate Professor of Oncology and Associate Professor of Gynecology and Obstetrics, Director of Gynecologic Cancer Trials at Johns Hopkins School of Medicine. OpenAlex indexes 348 publications with 5,970 citations (h-index 39); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
Stephanie Gaillard, MD, PHD, is Associate Professor of Oncology and Associate Professor of Gynecology and Obstetrics, Director of Gynecologic Cancer Trials at Johns Hopkins School of Medicine. The public record shows 348 publications with 5,970 citations (h-index 39), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 9 companies, 2 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · CA: a cancer journal for clinicians
- Top research focus: Ovarian cancer diagnosis and treatment
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 76.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 23 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Orion CorporationProgram year20252 payments
- AstraZeneca UK LimitedProgram year20251 payment
- Eisai Inc.Program year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.8%Poly(ADP-Ribose) Polymerase Inhibitor30.8%Lynparza100%Part D<11 patientsAromatase Inhibitor26.9%Letrozole100%Part D<11 patients+ 1 more class in this area
Nervous system
21.2%Phenothiazine21.2%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer
Johns Hopkins University
FY2026$442,761P50CA228991 - Overcoming Challenges Posed by Biomarker-Selective Clinical Trials: The Role of a Research Specialist
Johns Hopkins University
FY2026$105,619R50CA275932 - Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer
Johns Hopkins University
FY2025$309,182P50CA228991
Congress activity
Updated 23 Oct 2026
42 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva.
CA: a cancer journal for clinicians
Article2026 - Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid ReceptorArticle1,144 citations2005
- 02NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024Article385 citations2023
- 03
- 04Estrogen-related Receptors Stimulate Pyruvate Dehydrogenase Kinase Isoform 4 Gene ExpressionArticle159 citations2006
- 05Molecular Classification and Emerging Targeted Therapy in Endometrial CancerArticle158 citations2019
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
ocrahope.org/bio/stephanie-gaillard
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ocrahope.org ↗ - Other
hopkinsmedicine.org/profiles/results/directory/profile/10003765/stephanie-gaillard
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Duke University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - PhD in Cancer Biology
Duke University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Communications Committee Member
Society of Gynecologic Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sgo.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Jones, MD
Johns Hopkins School of Medicine
Jennifer Thorne, MD
Johns Hopkins School of Medicine
Christopher Hoffmann, MD
Johns Hopkins School of Medicine
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute